Halozyme Partners with Incyte to Develop Subcutaneous mutCALR Therapy Using ENHANZE

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two a...

July 21, 2026 | Tuesday | News
Samsung Biologics Announced CHF 1.46 Billion Tender Offer to Acquire PolyPeptide

  Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding ...

July 21, 2026 | Tuesday | News
Aqemia and Sanofi Expand AI-Driven Drug Discovery Collaboration

Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, announced the expansion of its mu...

July 20, 2026 | Monday | News
Dana-Farber, OSUCCC–James and IBCRF Launch Collaborative Research Initiative for Metastatic Inflammatory Breast Cancer

In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State Univ...

July 20, 2026 | Monday | News
Crown Bioscience Joins C-Path Coalition to Advance Human-Relevant Drug Development Methods

-Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined...

July 20, 2026 | Monday | News
Evogene and Tel Aviv University Launch AI-Driven Small Molecule Drug Discovery Initiative

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceuti...

July 10, 2026 | Friday | News
Danaher’s Abcam Partners with EpiCypher to Advance Epigenomics Research

Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, and EpiCypher®, the leading provider of ChIC/CU...

July 09, 2026 | Thursday | News
Genentech’s Divarasib Delivers Phase III Survival Benefit in KRAS G12C Non-Small Cell Lung Cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...

July 03, 2026 | Friday | News
Neurocrine Launches Phase 2 Trial of Crinecerfont in Children Under Four with Classic CAH

 Neurocrine Biosciences, Inc.  announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...

July 03, 2026 | Friday | News
Corten Capital Completes Beacon Intelligence Acquisition to Drive Next Phase of Growth

Corten Capital and Ampersand Capital Partners (“Ampersand”) are pleased to announce the completion of their acquisition of Beacon Intelligenc...

July 03, 2026 | Friday | News
Roche Launches AXELIOS 1 Sequencing Platform to Accelerate Same-Day Whole-Genome Research

AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...

June 30, 2026 | Tuesday | News
Verastem Reports Encouraging Early Clinical Activity for KRAS G12D Inhibitor VS-7375 Across Pancreatic, Colorectal and Lung Cancers

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, tod...

June 25, 2026 | Thursday | News
Revvity Expands Signals One Platform with AI-Powered Scientific Intelligence

Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals O...

June 24, 2026 | Wednesday | News
Transforming Contamination Control from Compliance Requirement to Strategic Advantage

Contamination control is no longer viewed solely through the lens of compliance. Across today's biopharmaceutical manufacturing landscape, it has become a ...

June 23, 2026 | Tuesday | Interaction

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close